Skip to main content

Table 3 Baseline characteristics of the study participants with and without incident CKD, Tehran Lipid and Glucose Study (1999–2014)

From: Application of survival tree analysis for exploration of potential interactions between predictors of incident chronic kidney disease: a 15-year follow-up study

Variables Men Women
Non CKD
n = 3002
Incident CKD
n = 793
p-value Non CKD
n = 2928
Incident CKD
n = 1515
p-value
Age (years) 39.1 (13.3) 50.3 (13.6) < 0.001 34.2 (10.6) 43.8 (12.4) < 0.001
Total length of stay in the city (years) 33.1 (12.5) 40.3 (14.1) < 0.001 28.9 (11.7) 36.5 (13.59) < 0.001
BMI (kg/m2) 25.7 (4.2) 26.3 (3.9) < 0.001 26.6 (5.1) 28.1 (4.8) < 0.001
Waist circumference (cm) 88.5 (11.5) 90.9 (11.1) < 0.001 84.5 (12.7) 88.9 (12.5) < 0.001
Wrist circumference (cm) 17.6 (0.9) 17.8 (0.9) < 0.001 15.7 (1.1) 16.1 (1.1) < 0.001
Hip circumference (cm) 96.6 (7.3) 97.1 (7.1) 0.086 102.8 (9.5) 104.6 (9.4) < 0.001
FPG (mmol/l) 4.9 (4.7–5.5) 5.2 (4.8–5.7) < 0.001 4.8 (4.5–5.2) 4.9 (4.7–5.5) < 0.001
TG (mmol/l) 1.7(1.1–2.5) 1.8(1.3–2.6) < 0.001 1.3(0.9–1.9) 1.6 (1.1–2.3) < 0.001
TC (mmol/l) 5.1 (1.1) 5.3 (1.1) < 0.001 5.1 (1.1) 5.5 (1.3) < 0.001
HDL-C (mmol/l) 0.9 (0.2) 0.9 (0.2) 0.48 1.1 (0.3) 1.2 (0.3) 0.210
eGFR (mL/min/1.73 m2) 79.2(10.6) 69.2 (7.4) < 0.001 77.1 (10.1) 68.8 (7.1) < 0.001
SBP (mmHg) 117.1 (15.4) 125.2 (19.7) < 0.001 111.8 (14.9) 120.1 (19.6) < 0.001
DBP (mmHg) 76.3 (10.3) 80.1(11.6) < 0.001 74.6 (10.1) 78.2 (10.8) < 0.001
Heart rate (beats/min) 75.5 (9.8) 74.47 (10.1) 0.015 83.5(11.8) 81.1 (11.4) < 0.001
Education
 Level 1 (illiterate) 518 (17.3) 221 (27.9)   560 (19.1) 455 (30.0)  
 Level 2 (< 9 years) 1858 (61.9) 370 (46.7) < 0.001 1884 (64.3) 719 (47.5) < 0.001
 Level 3 (9–12 years) 528 (17.6) 160 (20.2)   361 (12.3) 154 (10.2)  
 Level 4 (> 12 years) 98 (3.3) 42 (5.3)   123 (4.2) 187 (12.3)  
Marital status
 Single 686 (22.9) 57 (7.2)   503 (17.2) 91 (6.0)  
 Married 2302 (76.7) 725 (91.4) < 0.001 2325 (79.4) 1273 (84.0) < 0.001
 Divorced/widowed 14 (0.5) 11 (1.4)   100 (3.4) 151 (10.0)  
FH-CVD in female relatives 200 (6.7) 67 (8.4) 0.080 244 (8.3) 158 (10.4) 0.021
FH-CVD in male relatives 256 (8.5) 54 (6.8) 0.116 213 (7.3) 134 (8.8) 0.064
FHD in first-degree relatives 783 (26.1) 194 (24.5) 0.354 822 (28.1) 456 (30.1) 0.157
PAL
 Inactivea 2009 (71.2) 524 (69.4) 0.331 1908 (70.4) 1017 (70.9) 0.716
Smoking
 Never 1630 (55.1) 437 (56.2) 0.001 2747 (95.1) 1393 (93.6)  
 Past 378 (12.8) 132 (17.0) 33 (1.1) 24 (1.6) 0.101
 Current 950 (32.1) 208 (26.8) 109 (3.8) 72 (4.8)  
Use of blood lipid lowering drugs 41 (1.4) 22 (2.8) 0.006 49 (1.7) 65 (4.3) < 0.001
Use of blood glucose lowering drugs 55 (1.8) 45 (5.7) < 0.001 54 (1.8) 80 (5.3) < 0.001
Use of anti hypertensive drugs 59 (2.0) 54 (6.8) < 0.001 90 (3.1) 132 (8.7) < 0.001
Use of aspirin 286 (9.5) 108 (13.6) 0.001 172 (5.9) 151 (10.0) < 0.001
Use of diuretics 12 (0.4) 10 (1.3) 0.004 37 (1.3) 34 (2.2) 0.013
Prevalence CVD 87 (2.9) 53 (6.7) < 0.001 30 (1.0) 49 (3.2) < 0.001
  1. Figures are either mean (SD) or N (%) for continuously and categorically distributed variables, respectively
  2. TLGS Tehran Lipid and Glucose Study, BMI body mass index, FPG fasting plasma glucose, TG triglyceride, TC total cholesterol, HDL-C HDL cholesterol, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, FH-CVD family history of premature cardiovascular disease, FHD family history of diabetes mellitus, PAL physical activity level, CVD cardiovascular disease
  3. aDoing exercise or labor less than three times a week or performing activities achieving < 600 metabolic equivalent of task (MET)